Exscientia Logo

Pipeline

Our pipeline demonstrates the ability of our AI-driven drug discovery platform to create precision engineered, patient-centric therapeutic candidates.

Programme

Target

Late Discovery

IND-enabling

Phase 1/2

Pivotal / Approved

Exscientia Rights

PKC-theta is in a Phase 1 healthy volunteer (HV) study; AML = acute myeloid leukaemia; SCLC = small-cell lung cancer